A phase I trial of OX40-enhanced CAR-T therapy showed remissions in several B-cell non-Hodgkin lymphomas, researchers ...
Results from a phase I clinical trial led by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer ...
Results from a phase I clinical trial show enhanced chimeric antigen receptor (CAR) T-cell therapy improved outcomes for ...
In the 20 years since the FDA’s approval of rituximab for rheumatoid arthritis, trials and real-world use of B-cell depleting therapies have resulted in surprising successes and unexpected setbacks in ...
A research team led by associate professors Yohei Funakoshi and Kimikazu Yakushijin and Professor Hironobu Minami of the ...
Single-cell transcriptomics across multiple COVID-19 cohorts reveals that peripheral B cell dysregulation, marked by plasmablast expansion and naive B cell depletion, is associated with post-COVID ...
The pGen-SHM plot combines BCR generation probability and somatic hypermutation to track humoral immune recovery after stem cell transplantation. The approach has revealed distinct maturation patterns ...
B-cell lymphoma is a type of non-Hodgkin lymphoma. It’s also the most common type of lymphoma. Approximately 85% of all lymphomas in the United States are B-cell lymphomas. Non-Hodgkin lymphomas are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results